ChemPartner has a top-tier antibody drug conjugate (ADC) team spanning multiple areas, such as antibody development, medicinal chemistry, DMPK, and in vitro/in vivo pharmacology. In addition to individual function service packages, ChemPartner also provides all-in-one ADC development service packages from antibody generation to IND filing. 

 Our scientists are highly skilled in the design and synthesis of a variety of toxins and linkers, such as the mechanistically diverse MMAE/MMAF, Maytansine derivatives, Duocarmycin, Nemorubicin, and pyrrolobenzodiazepines. We purify and characterize ADCs using state-of-the-art technologies. A dedicated, certified, high-potency lab is fully operational and capable of handling Active Pharmaceuticals Ingredients (APIs) with Occupational Exposure Limit (OEL) < 1 μg/m3 at scale up to 50 grams. 

 Our biologics team is able to develop antibodies from scratch using single B cell cloning, phage display, or hybridoma approaches. Our manufacturing (CMC) team has GMP compliant antibody production and fill-finish capacity of up to 400 grams. 

 The ADC team has early discovery, optimization, and evaluation capacity using different antibody, linker, and toxin combinations. The GLP CMC facility has the production capacity for producing up to 40 grams.

 All ADC-related functions and developments are fully supported with a well-equipped, state-of-the-art analytical facility. The ADC team has worked with many pharmaceutical and biotech companies on novel toxins to create novel ADCs with additional mechanisms of action.

Flexible Early Clinical Development

ADC Analytical Services

Case Study on T-DM1 (Kadcyla)

START YOUR JOURNEY
Phase
Modality
Therapeutic Area